ReviewTherapeutics and clinical risk management2015
Apixaban for the prophylaxis and treatment of deep vein thrombosis and pulmonary embolism: an evidence-based review.
Review in Therapeutics and clinical risk management, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 33 citations in OpenAlex.
- Drugs to Prevent and Treat Venous Thromboembolic Disease During Pregnancy.Clinics in perinatology · 2026Review
- Comparing Venous Thromboembolism Prophylactic Agents After Hip Fracture Surgery: A National Database Study.Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews · 2022Article
- Comparing the Efficacy and Safety of Apixaban Versus Warfarin in Morbidly Obese Patients.Cureus · 2022Article
- Atraumatic Splenic Rupture on Direct Oral Anticoagulation.Journal of community hospital internal medicine perspectives · 2022Article
- Clinical Efficacy of Conventional Heparin Anticoagulation Combined with Apixaban in the Treatment of Patients with Cerebral Venous Thrombosis and Its Effect on Serum D-Dimer and FIB Expression.Computational and mathematical methods in medicine · 2021Article
- Surgical intervention in patients with proximal femoral fractures confirmed positive for COVID-19-a report of 2 cases.Acta orthopaedica · 2020Article
- Mesenteric venous thrombosis as a complication of appendicitis in an adolescent: A case report and literature review.Medicine · 2019Review
- Comparison of apixaban and rivaroxaban for anticoagulant effect after lumbar spine surgery: a single-center report.Future science OA · 2018Article
- Reduced dose apixaban resolving dual cardiac chamber thrombi in a patient with ischaemic cardiomyopathy in sinus rhythm.BMJ case reports · 2017Article
- [Monitoring of NOAC].Medizinische Klinik, Intensivmedizin und Notfallmedizin · 2017Article
- Quick reference guide to apixaban.Vascular health and risk management · 2017Review
- Cost Effectiveness of Apixaban and Enoxaparin for the Prevention of Venous Thromboembolism After Total Knee Replacement in China.Clinical drug investigation · 2016Article
- Left atrium mass in a patient with breast cancer: a case report.Journal of medical case reports · 2016Article
- Direct oral anticoagulants and venous thromboembolism.European respiratory review : an official journal of the European Respiratory Society · 2016Review
- Silent but Deadly: A Conservative Approach to Pulmonary Artery Pseudoaneurysm.Journal of investigative medicine high impact case reportsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Venous thromboembolism (VTE) results in significant morbidity and mortality. The prevention and treatment of VTE is managed with anticoagulant therapy, historically parenteral anticoagulants such as unfractionated heparin, low molecular weight heparin, and fondaparinux, and oral vitamin K antagonists such as warfarin. In the last few years, several target-specific oral anticoagulants have been developed, including the direct thrombin inhibitor dabigatran and anti-Xa inhibitors rivaroxaban, apixaban, and edoxaban. The target-specific oral anticoagulants have proven to be noninferior to vitamin K antagonists and heparins in the prevention and treatment of VTE. This review will focus on the pharmacology, clinical trial data, and laboratory assessment of apixaban. Moreover, perioperative management, use in special populations, and management of bleeding complications in patients taking apixaban for the prevention and treatment of VTE will also be discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.